We develop practical tests that help doctors choose the best treatments for each patient and/or accurately confirm diagnosis or disease prognosis. Imagine if your doctor had a crystal ball that could predict which medicine would work best for you - that's what we're creating!
AI-Driven Biomarker Discovery
We use advanced artificial intelligence (AI) to find special signs in your body that tell us how you'll respond to certain medication. It's like teaching a computer to read the secret language of your body and how it would react to certain drugs.
Treatment Response Predictors (TRPs)
Our initial product is a test that predicts if a specific medicine for autoimmune diseases will work for you. It's like having a crystal ball that tells doctors what will work for you specifically.
Collaborative Partnerships
We team up with other leading companies to make our tests even better. It's like joining forces to fight healthcare’s biggest problems!
Focus on Healthcare System Improvement
We want to help our system save the $1 trillion that's wasted on medicines that simply don't work. Imagine if we could use that money to make everyone healthier instead!
Biomarker Discovery
• Utilization of the Emerge® AI platform, a proprietary quantitative artificial intelligence tool.
• Designed to analyze complex non-linear systems in biopharma.
• Produces transparent, unbiased, and accurate predictive algorithms.
• Boasts a 100% validation success rate, compared to the industry standard of 90%+ failure rate.
Collaborative & Iterative Process
• We team up with other leading companies to make our tests even better.
• Including some of the best scientific advisors among their respective fields.
• We employ continuous refinement and validation of algorithmic biomarkers as new data becomes available.
• Along with, consistently updating our technology to refine and address market challenges.
• We have the potential for incorporation into dynamic product labels for optimal treatment decisions.
TNF-alpha Inhibitor (TNFi)
• Addresses the critical issue of treatment non-response in TNFi therapy
• Recently completed analytical validation
• Aims to identify those who respond and do not respond to TNFi therapy
• Potential to reduce unnecessary side effects, delay disease progression and financial burden
Contact Us
